FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.	C. 20549
----------------	----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PASQUALONE FRANK					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Theravance Biopharma, Inc. [ TBPH ]							5. Relationship of Reporting (Check all applicable) Director Officer (give title				10% O	vner	
(Last) (First) (Middle) C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD					3. Date of Earliest Transaction (Month/Day/Year) 11/19/2021								1	X below) below) SVP, CHIEF BUSINESS OFFICER				
ISCO CA				4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	·						
	Table	I - Noi	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or E	Benef	ficiall	y Own	ed			
Date			Execution D		ution I	ıtion Date, Tı C		ansaction Disposed (ode (Instr. 5)					Securit Benefic Owned	urities eficially ned Following		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s)			(111341.4)		
Ordinary Shares 11/19/2			2021				F		3,779(1)	I	) [	\$8.36	6 429,783			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
itle of ivative Conversion or Exercise Price of Derivative Security  2. 3. Transaction Date Execution Date, if any (Month/Day/Year)		Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Dispo of (D (Insti	rative rities ired r osed )	Expiration Da (Month/Day/Y		te	Amou or Numb of		De Se (In	erivative ecurity	derivative Securities Beneficiall Owned Following Reported	у	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
	(Fire ERAVANCI SAN CA ISCO (St  Security (Inst  Shares	(First) (NERAVANCE BIOPHARMA FEWAY BLVD  SAN GA 90  (State) (Z  Table  Security (Instr. 3)  Shares  Tat  2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) ERAVANCE BIOPHARMA US, INTEWAY BLVD  SAN GA 94080  (State) (Zip)  Table I - Note Security (Instr. 3)  Shares  Table II -  Conversion or Exercise Price of Derivative Price of Derivative (Month/Day/Year)	(First) (Middle)  ERAVANCE BIOPHARMA US, INC.  FEWAY BLVD  SAN CA 94080  (State) (Zip)  Table I - Non-Deriva  Security (Instr. 3)  2. Transac Date (Month/Da)  Shares  11/19/2  Table II - Derivatir (e.g., pu  2. (Month/Day/Year)  3A. Deemed Execution Date, if any (Month/Day/Year)	(First) (Middle)  ERAVANCE BIOPHARMA US, INC.  SAN CA 94080  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  Shares  11/19/2021  Table II - Derivative Security (E.g., puts, cather and part of the perivative Security (Month/Day/Year)  2. Table II - Derivative Security (Month/Day/Year)  Shares  2. Table II - Derivative Security (Month/Day/Year)  All Derivative Security (Month/Day/Year)  All Demend Execution Date, if any (Month/Day/Year) (Month/Day/Year)	Therava  (First) (Middle)  ERAVANCE BIOPHARMA US, INC.  FEWAY BLVD   Table I - Non-Derivative Security (Instr. 3)  Table II - Derivative Security (Month/Day/Year)  Table II - Derivative Security (e.g., puts, calls, v.g., puts, p	Theravance  (First) (Middle)  ERAVANCE BIOPHARMA US, INC.  TEWAY BLVD  Table I - Non-Derivative Securities  Security (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities  Table II - Derivative Securities  (e.g., puts, calls, warra  2. Conversion or Exercise Price of Derivative Security (Month/Day/Year)  Table II - Derivative Securities  (a.g., puts, calls, warra  (A) of Derivative Security (Month/Day/Year)  Table II - Derivative Securities  (b.g., puts, calls, warra  (c.g., puts, calls, warra  (d.) of Derivative Security (A) of Derivat	Theravance Biop  (First) (Middle)  ERAVANCE BIOPHARMA US, INC.  (Stave) (Zip)  Table I - Non-Derivative Securities Acques (Month/Day/Year)  Shares  Table II - Derivative Securities Acques (e.g., puts, calls, warrants, of Derivative Security  (Month/Day/Year)  Table II - Derivative Securities Acques (e.g., puts, calls, warrants, of Derivative Security  (Month/Day/Year)  3. Date of Earliest Transatin 11/19/2021  4. If Amendment, Date of Execution Date, if any (Month/Day/Year)  Execution Date (e.g., puts, calls, warrants, of Derivative Security (A) or Disposed of (D) (Instr. 3, 4 and 5)  (Instr. 3, 4 and 5)	Theravance Biopharm.  (First) (Middle)  ERAVANCE BIOPHARMA US, INC.  TEWAY BLVD  Table I - Non-Derivative Securities Acquired, [Month/Day/Year]  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Table II - Derivative Securities Acquired, If any (Month/Day/Year)  Table II - Derivative Securities Acquired, If any (Month/Day/Year)  Table II - Derivative Securities Acquired, If any (Month/Day/Year)  2. Transaction Date (e.g., puts, calls, warrants, option of Exercise Price of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  Date	Theravance Biopharma, In  (First) (Middle)  ERAVANCE BIOPHARMA US, INC.  TEWAY BLVD  3. Date of Earliest Transaction (Month, 11/19/2021  4. If Amendment, Date of Original Filed Execution Date, (Month/Day/Year)  Table I - Non-Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Shares  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Shares  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Shares  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Shares  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Shares  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Shares  Table II - Derivative Securities Acquired, Disposed of (Date (Month/Day/Year))  Shares  Date (Month/Day/Year)  A. Deemed Execution Date, if any (Month/Day/Year)  Shares  Date (Date (Month/Day/Year))  A. Deemed Execution Date, if any (Month/Day/Year)  Shares  Date (Date (Month/Day/Year))  A. Deemed Execution Date, if any (Month/Day/Year)  Shares  Date (Date (Month/Day/Year))  A. Deemed Execution Date, if any (Month/Day/Year)  Shares  Date (Date (Month/Day/Year))	Theravance Biopharma, Inc. [TBPI]  SERAVANCE BIOPHARMA US, INC.  SAN ISCO CA 94080  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of Execution Date, (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of Security (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of Code (Instr. 8)  Date Exercisable and Expiration Date (Month/Day/Year) (Instr. 3, 4)  And 5)  Date Exercisable and Expiration Date (Instr. 3, 4)  Date Exercisable and Expiration Date (Instr. 3, 4)  Expiration Date (Month/Day/Year) (Instr. 3, 4)  Date Exercisable and Expiration Date (Month/Day/Year) (Instr. 3, 4)  Date Exercisable and Expiration Date (Instr. 3, 4)  Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year)	Theravance Biopharma, Inc. [TBPH]  Theravance Biopharma, Inc. [TBPH]  3. Date of Earliest Transaction (Month/Day/Year)  11/19/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)  Table I - Non-Derivative Securities Acquired, Disposed of, or Earliest Transaction (Month/Day/Year)  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Code (Instr. any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Code (Instr. any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of, or Be (e.g., puts, calls, warrants, options, convertible se (E.g., puts, calls, warrants, options, convertible se (Instr. and Security (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Be (E.g., puts, calls, warrants, options, convertible se (Instr. and Security (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Be (E.g., puts, calls, warrants, options, convertible se (Instr. and Security (Month/Day/Year) (Month/Day/Year)  Date Expiration  Date Expiration	Theravance Biopharma, Inc. [TBPH]  3. Date of Earliest Transaction (Month/Day/Year)  SAN GA 94080  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Benefication (Month/Day/Year)  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Shares  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Shares  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Benefication (Code (Instr. B))  Table II - Derivative Securities Acquired, Disposed of, or Benefication (B) (Instr. B)  Table II - Derivative Securities Acquired, Disposed of, or Benefication (Code (Instr. B))  Table II - Derivative Securities Acquired, Disposed of, or Benefication (B) (Instr. B)  Table II - Derivative Securities Acquired, Disposed of, or Benefication (B) (Instr. B)  Table II - Derivative Securities Acquired (A) or Derivative Securities (Month/Day/Year)  Acquired (Month/Day/Year)  Date Exercisable and Expiration Date (Month/Day/Year)  Total end Amount or Derivative Securities (Acquired (A) or Derivative Securities (Month/Day/Year)  Date Exercisable and Expiration Date (Instr. B)  Total end Amount or Numl (Instr. B)  Amount (Instr. B)  Amount (Instr. B)  Amount (Instr. B)  Amount (Instr. B)  Table II - Derivative Securities (Month/Day/Year)  Date Exercisable and Expiration Date (Instr. B)  Total end (Instr. B)  Amount (Instr. B)	Theravance Biopharma, Inc. [TBPH]  (Cher X (First) (Middle)  ERAVANCE BIOPHARMA US, INC. 11/19/2021  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficiall Security (Instr. 3)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Shares  11/19/2021	Theravance Biopharma, Inc. [TBPH]  Theravance Biopharma, Inc. [Table Included	Theravance Biopharma, Inc. [TBPH]    Check all applicable   Director   Director   X   Director   Director   Director   X   Director   Director	Theravance Biopharma, Inc. [TBPH] Check all applicable) Director X Officer (give title below) SVP, CHIEF BUSINE SAN CEA 94080  SAN CA 94080  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Form (Month/Day/Year) [Sign of Code (Instr. 3)] [A Deemed Execution Date, (Month/Day/Year)] [A Deemed Execution Date, or Securities Acquired, Disposed of, or Beneficially Owned Form (Instr. 3 and 4)] [Check all applicable) Director X Officer (give title below) SVP, CHIEF BUSINE SVP, CHIEF BUSINE SVP, CHIEF BUSINE SAN (Month/Day/Year) [A Deemed Execution Date, if any (Month/Day/Year)] [A Deemed Execution Date, if any (Month/Day/Y	Theravance Biopharma, Inc. [TBPH] Check all applicable) Director 10% Over the Other (special polyment) SAN CA 94080  SAN CA 94080  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year)  Table I - Non-Derivative Securities Acquired, Disposed of (polyment) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities Securities Acquired (Nonth/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities  Shares  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities  Shares  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities  Shares  Table II - Derivative Securities Acquired (Nonth/Day/Year)  Amount of Securities Securi

## **Explanation of Responses:**

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market

/s/ Brett A. Grimaud, Attorney-in-Fact

11/23/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.